• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Perspective Therapeutics, Inc.

    < Previous 1 2 Next >
    News headline image
    Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate at Upcoming Investor Conferences in August
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate at Upcoming May Investor Conferences
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate at Upcoming April Investor Conferences
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces $87.4 Million Private Placement
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate at Upcoming Investor Conferences
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.